Validation consultants quickly realize that one of the first things their client wants is the execution of a validation and compliance
Gap Analysis Tool (GA). A reassurance that all discrepancies have been identified and reconciled - in house. When an existing problem is not discovered, acknowledged and remedied, and visiting regulator discovers it, the issues can be, and very often are damaging to individual careers, and to the company.
Execution of a Gap Analysis Tool gives tremendous reassurance that the validation and compliance requirements of the company are being met.
The Gap Analysis tool allows you to systematically challenge the company’s
cGMP compliance policies and procedures, comparing them with the regulatory expected standards and enables you to draw up a list of all the delinquencies. Until you can highlight the company’s deficiencies, you are not able to scope the task of becoming compliant. It really is difficult and verging on the impossible to put resources together for an unmeasured task.
Recently the FDA has created and approved the
Quality Systems (QS) guideline to impart a consistent set of requirements that will compliment the current cGMP’s and provide the tools for industry to implement effective QS’s that will guarantee the best product quality for the customers. The next step for most companies is to perform a GA to determine what actions are necessary for them to be in compliance with the new guideline. The GA must be conducted as a planned / organized process and must be documented. The personnel conducting the GA compliance and validation analysis must also be qualified and must prioritize the areas to be inspected. It must be verified that the cascade of documents used in qualifying equipment i.e.
VMP -
VP -
URS -
DQ -
IQ -
OQ -
P1Q -
P2Q, are in place and all of them have have been constructed in accordance with the company's practices and procedures manual.